naltrexone has been researched along with HIV Infections in 59 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 2 (3.39) | 18.2507 |
| 2000's | 15 (25.42) | 29.6817 |
| 2010's | 27 (45.76) | 24.3611 |
| 2020's | 15 (25.42) | 2.80 |
| Authors | Studies |
|---|---|
| Arnatt, CK; El-Hage, N; Falls, BA; Hauser, KF; Knapp, PE; Masvekar, RR; Nicola, AV; Raborg, TJ; Selley, DE; Yuan, Y; Zhang, Y | 1 |
| Cook, RR; Fanucchi, L; Foot, C; King, C; Korthuis, PT; Lucas, GM; Lum, PJ; Rodriguez, A; Tookes, H; Torralva, R; Vergara-Rodriguez, P; Waddell, EN | 1 |
| Baker, R; Fanucchi, LC; Hoffman, KA; Jacobs, P; Korthuis, PT; Kunkel, LE; Lum, PJ; McCarty, D; Ponce Terashima, J | 1 |
| Altice, FL; Bachireddy, C; Ding, R; Duerr, AC; Galvez de Leon, SJ; Gonzales, P; Grieco, A; Lama, J; Ulrich, A | 1 |
| Bachrach, K; Bielavitz, S; Collins, JA; Cook, RR; Fanucchi, LC; Hoffman, KA; Jacobs, P; Jelstrom, E; Korthuis, PT; Kunkel, LE; Lucas, GM; Lum, PJ; Matthews, A; McCarty, D; Oden, N; Payne, EH; Rodriguez, AE; Sorensen, JL; Tookes, H; Vergara-Rodriguez, P; Waddell, EN | 1 |
| Donohoe, T; Garner, BR; Gordon, T; Gotham, HJ; Knudsen, HK; Loyd, K; Martin, EG; Toro, AK; Tueller, SJ; Zulkiewicz, BA | 1 |
| Abdel-Mohsen, M; Azzoni, L; Fair, M; Giron, LB; Hiserodt, E; Lalley-Chareczko, L; Lynn, K; Montaner, LJ; Mounzer, K; Trooskin, S; Vadrevu, S; Zhao, L | 1 |
| Di Paola, A; Lier, AJ; Seval, N; Springer, SA; Vander Wyk, B | 1 |
| Blokhina, E; Bushara, N; Cheng, DM; Gnatienko, N; Krupitsky, E; Lioznov, D; Lunze, K; Quinn, E; Raj, A; Rosen, S; Samet, JH; Truong, V | 1 |
| Alam, F; Dhadley, S; Roberts, P; Townley, J; Webster, R; Wright, N | 1 |
| Baker, R; Hoffman, KA; Korthuis, PT; Kunkel, LE; Lum, PJ; McCarty, D; Waddell, EN | 1 |
| Akgün, K; Bryant, K; Crystal, S; Edelman, EJ; Fiellin, DA; Fiellin, LE; Gaither, JR; Gordon, AJ; Goulet, JL; Justice, AC; Korthuis, PT; Kraemer, KL; Marshall, BDL; McGinnis, KA; Oldfield, BJ; Williams, EC | 1 |
| Altice, FL; Ding, R; Duerr, A; Gonzales, P; Grieco, A; Ignacio, RB; Lama, JR; Pinto-Santini, D; White, E | 1 |
| Farhadian, M; Farhadian, N; Farnia, V; Moradi, S; Rezaeian, S; Shahlaei, M; Zamanian, MH | 1 |
| Brumback, B; Bryant, K; Bryant, V; Cook, RL; Hahn, JA; Richards, VL; Sajdeya, R; Villalba, K; Wang, Y | 1 |
| Bendiks, S; Blokhina, E; Bryant, K; Cheng, DM; Gnatienko, N; Krupitsky, E; Samet, JH; Tsui, JI; Verbitskaya, E; Vetrova, M | 1 |
| Biondi, BE; Forray, A; Frank, CA; Springer, SA | 1 |
| Dionne, R; Fishman, M; Gryczynski, J; Lertch, E; Ludwig, A; Mitchell, SG; Monico, LB; Schwartz, RP | 1 |
| Altice, FL; Azar, MM; Barbour, R; Di Paola, A; Krishnan, A; Springer, SA | 1 |
| Chokron Garneau, H; Glasner, S; Rawson, R; Ray, LA; Venegas, A | 1 |
| Brumback, B; Bryant, K; Cohen, M; Cook, RL; Hu, X; Karki, M; Mai, D; Rathore, M; Thoma, K; Weber, KM; Young, M | 1 |
| Brumback, B; Chen, X; Cook, RL; Hahn, JA; Miguez, MJ; Wang, Y; Zhou, Z | 1 |
| Edelman, EJ; Marshall, BDL; Williams, EC | 1 |
| Altice, FL; Azar, MM; Barbour, R; Biondi, BE; Desabrais, M; Di Paola, A; Lincoln, T; Skiest, DJ; Springer, SA | 1 |
| Altice, FL; Azar, MM; Barbour, R; Di Paola, A; Springer, SA | 1 |
| Brown, ST; Bryant, KJ; Edelman, EJ; Fiellin, DA; Fiellin, LE; Hansen, N; Holt, SR; Justice, AC; Kyriakides, TC; Moore, BA; Virata, M | 1 |
| Fanucchi, L; Korthuis, PT; Springer, SA | 1 |
| Kunoe, N; Lee, JD | 1 |
| Blokhina, E; Burakov, A; Bushara, N; Gross, R; Krupitsky, E; Langleben, D; Lioznov, D; Mamontova, O; Masalov, D; Palatkin, V; Poole, S; Verbitskaya, E; Vetrova, M; Woody, G; Yaroslavtseva, T; Zvartau, E | 1 |
| Brumback, B; Bryant, K; Cook, RL; Espinoza, L; Lewis, JE; Miguez, MJ; Quiros, C; Zhou, Z | 1 |
| Altice, FL; Di Paola, A; Herme, M; Springer, SA | 1 |
| Altice, FL; Di Paola, A; Herme, M; Lincoln, T; Skiest, DJ; Springer, SA; Vagenas, P | 1 |
| Altice, FL; Desabrais, M; Di Paola, A; Lincoln, T; Skiest, DJ; Springer, SA | 1 |
| Altice, FL; Brown, SE; Di Paola, A; Springer, SA | 1 |
| Krupitsky, E; Woody, GE; Zvartau, E | 1 |
| Fitzgerald, TT; Gordon, MS; O'Brien, CP; O'Grady, KE; Vocci, FJ | 1 |
| Ahamad, K; Arenas, V; Ha, D; Korthuis, PT; Kunkel, LE; Lindblad, R; Lum, PJ; Mandler, RN; McCarty, D; Oden, NL; Sorensen, JL; Vergara-Rodriguez, P; Wood, E | 1 |
| Chawarski, MC; Mazlan, M; Schottenfeld, RS | 3 |
| Dolan, K; Larney, S | 1 |
| Metzger, DS; Zhang, Y | 1 |
| Metzger, DS; O'Brien, CP; Woody, GE | 1 |
| Jones, HE; Kirtadze, I; O'Grady, KE; Otiashvili, D | 1 |
| Bryant, K; Fiellin, DA; Goulet, JL; Justice, AC; McGinnis, KA; Sullivan, LE; Tate, JP; Tetrault, JM | 1 |
| Memisoglu, A; Mitchell, MC; Silverman, BL | 1 |
| Douglas, SD; Guo, CJ; Ho, WZ; Moss, J; Yuan, CS | 1 |
| Douglas, SD; Ho, WZ; Tan, N; Wang, X; Wang, YJ; Zhang, T | 1 |
| Douglas, SD; Ho, WZ; Metzger, DS; O'Brien, CP; Peng, JS; Wang, X; Zhang, T | 1 |
| Cubells, JF; Tang, YL; Zhao, C; Zhao, D | 1 |
| Bespalov, AY; Burakov, AM; Didenko, TY; Egorova, VY; Grinenko, AY; Ivanova, EB; Krupitsky, EM; Masalov, DV; Neznanov, NG; O'Brien, CP; Romanova, TN; Tsoy, MV; Verbitskaya, EV; Woody, GE; Zvartau, EE | 1 |
| Bridden, C; Cheng, DM; Edwards, EM; Egorova, VY; Krupitsky, EM; Raj, A; Samet, JH; Walley, AY; Woody, GE; Zvartau, EE | 1 |
| Nightingale, SL | 1 |
| Gibbons, N; Kapasi, AA; Mattana, J; Singhal, PC | 1 |
| Douglas, SD; Guo, CJ; Ho, WZ; Li, Y; Tian, S; Wang, X | 1 |
| Friedland, G; Jatlow, P; Kosten, TR; McCance-Katz, EF; Rainey, PM | 1 |
8 review(s) available for naltrexone and HIV Infections
| Article | Year |
|---|---|
Effectiveness of naltrexone treatment for alcohol use disorders in HIV: a systematic review.
Topics: Adult; Alcoholism; Female; HIV Infections; Humans; Naltrexone; Narcotic Antagonists; Treatment Outcome; Young Adult | 2020 |
Addressing unhealthy alcohol use among people living with HIV: recent advances and research directions.
Topics: Alcohol Deterrents; Alcoholism; Biomedical Research; Disease Management; HIV Infections; Humans; Mass Screening; Naltrexone; Referral and Consultation; Treatment Outcome | 2018 |
Medications for Treatment of Opioid Use Disorder among Persons Living with HIV.
Topics: Buprenorphine; HIV Infections; Humans; Methadone; Naltrexone; Opioid-Related Disorders; Treatment Outcome | 2019 |
Antagonist Models for Relapse Prevention and Reducing HIV Risk.
Topics: HIV Infections; Humans; Naltrexone; Narcotic Antagonists; Opioid-Related Disorders; Receptors, Opioid, mu; Risk Factors; Russia; Secondary Prevention | 2016 |
A literature review of international implementation of opioid substitution treatment in prisons: equivalence of care?
Topics: Buprenorphine; Heroin Dependence; HIV Infections; Humans; International Cooperation; Methadone; Naltrexone; Narcotic Antagonists; Patient Care; Prisoners; Prisons | 2009 |
Drug treatment as HIV prevention: expanding treatment options.
Topics: Alcoholism; Buprenorphine; Clinical Protocols; Drug Users; Health Promotion; HIV Infections; Humans; Methadone; Naltrexone; Opiate Substitution Treatment; Risk Reduction Behavior; Risk-Taking; Substance Abuse, Intravenous; Substance-Related Disorders | 2010 |
Drug treatment as HIV prevention: a research update.
Topics: Anti-HIV Agents; Buprenorphine; Guideline Adherence; HIV Infections; Humans; Naltrexone; Risk Reduction Behavior; Sexual Behavior | 2010 |
Opiate addiction in China: current situation and treatments.
Topics: Buprenorphine; China; Clonidine; Drugs, Chinese Herbal; HIV Infections; Humans; Methadone; Naltrexone; Narcotic Antagonists; Narcotics; Opioid-Related Disorders; Substance Abuse, Intravenous; Substance Withdrawal Syndrome; Sympatholytics | 2006 |
28 trial(s) available for naltrexone and HIV Infections
| Article | Year |
|---|---|
Associations between fentanyl use and initiation, persistence, and retention on medications for opioid use disorder among people living with uncontrolled HIV disease.
Topics: Buprenorphine; Delayed-Action Preparations; Fentanyl; HIV Infections; Humans; Male; Middle Aged; Naltrexone; Narcotic Antagonists; Opioid-Related Disorders | 2021 |
Viral Suppression Levels in Men Who Have Sex With Men and Transgender Women With Newly Diagnosed HIV and Alcohol Use Disorder in Peru: Results From a Randomized, Double-Blind, Placebo-Controlled Trial Using Oral Naltrexone.
Topics: Alcoholism; Female; HIV Infections; Homosexuality, Male; Humans; Male; Naltrexone; Peru; Sexual and Gender Minorities; Transgender Persons | 2022 |
HIV clinic-based extended-release naltrexone versus treatment as usual for people with HIV and opioid use disorder: a non-blinded, randomized non-inferiority trial.
Topics: Analgesics, Opioid; Delayed-Action Preparations; Female; HIV Infections; Humans; Injections, Intramuscular; Male; Naltrexone; Narcotic Antagonists; Opioid-Related Disorders | 2022 |
Maintenance on extended-release naltrexone is associated with reduced injection opioid use among justice-involved persons with opioid use disorder.
Topics: Analgesics, Opioid; Buprenorphine; Delayed-Action Preparations; Hepatitis C; HIV Infections; Humans; Injections, Intramuscular; Methadone; Naltrexone; Narcotic Antagonists; Opioid-Related Disorders; RNA; Social Justice | 2022 |
Rapid access to antiretroviral therapy, receipt of naltrexone, and strengths-based case management versus standard of care for HIV viral load suppression in people with HIV who inject drugs in Russia (LINC-II): an open-label, randomised controlled trial.
Topics: Case Management; Female; HIV Infections; Humans; Male; Naltrexone; Opioid-Related Disorders; Russia; Standard of Care; Viral Load | 2023 |
Safety of oral naltrexone in HIV-positive men who have sex with men and transgender women with alcohol use disorder and initiating antiretroviral therapy.
Topics: Administration, Oral; Adolescent; Adult; Alcoholism; Anti-HIV Agents; Female; HIV Infections; Homosexuality, Male; Humans; Male; Middle Aged; Naltrexone; Safety; Transgender Persons; Treatment Outcome; Young Adult | 2020 |
Secondary Analysis of a Randomized Clinical Trial of Naltrexone Among Women Living With HIV: Correlations Between Reductions in Self-Reported Alcohol Use and Changes in Phosphatidylethanol.
Topics: Adult; Alcohol Deterrents; Alcohol Drinking; Female; Florida; Glycerophospholipids; HIV Infections; Humans; Middle Aged; Naltrexone; Self Report | 2021 |
Pilot study of tolerability and safety of opioid receptor antagonists as novel therapies for chronic pain among persons living with HIV with past year heavy drinking: a randomized controlled trial.
Topics: Alcoholism; Chronic Pain; HIV Infections; Humans; Naltrexone; Narcotic Antagonists; Pilot Projects; Treatment Outcome | 2023 |
Gender differences among criminal justice-involved persons living with HIV interested in extended-release naltrexone treatment.
Topics: Criminal Law; Delayed-Action Preparations; Female; HIV Infections; Humans; Injections, Intramuscular; Male; Naltrexone; Narcotic Antagonists; Opioid-Related Disorders; Sex Factors | 2021 |
Extended-release naltrexone reduces alcohol consumption among released prisoners with HIV disease as they transition to the community.
Topics: Adult; Alcohol Drinking; Delayed-Action Preparations; Double-Blind Method; Female; HIV Infections; Humans; Male; Middle Aged; Naltrexone; Narcotic Antagonists; Prisoners; Treatment Outcome; Young Adult | 2017 |
Acceptability and feasibility of a randomized clinical trial of oral naltrexone vs. placebo for women living with HIV infection: Study design challenges and pilot study results.
Topics: Adult; Alcoholism; Black or African American; Double-Blind Method; Female; HIV Infections; Humans; Medication Adherence; Middle Aged; Naltrexone; Narcotic Antagonists; Pilot Projects; Substance-Related Disorders | 2017 |
Phosphatidylethanol in Comparison to Self-Reported Alcohol Consumption Among HIV-Infected Women in a Randomized Controlled Trial of Naltrexone for Reducing Hazardous Drinking.
Topics: Adult; Alcohol Deterrents; Alcohol Drinking; Alcoholism; Biomarkers; Female; Glycerophospholipids; HIV Infections; Humans; Middle Aged; Naltrexone; Self Report | 2018 |
Extended-Release Naltrexone Improves Viral Suppression Among Incarcerated Persons Living With HIV With Opioid Use Disorders Transitioning to the Community: Results of a Double-Blind, Placebo-Controlled Randomized Trial.
Topics: Adult; Criminal Law; Delayed-Action Preparations; Double-Blind Method; Female; Follow-Up Studies; HIV Infections; HIV-1; Humans; Injections, Intramuscular; Male; Middle Aged; Multivariate Analysis; Naltrexone; Narcotic Antagonists; Opioid-Related Disorders; Prisoners; Prospective Studies; Research Design; RNA, Viral; Time Factors; Treatment Outcome; Viral Load | 2018 |
Extended-release Naltrexone Improves Viral Suppression Among Incarcerated Persons Living with HIV and Alcohol use Disorders Transitioning to the Community: Results From a Double-Blind, Placebo-Controlled Trial.
Topics: Adult; Alcohol Deterrents; Alcoholism; Delayed-Action Preparations; Double-Blind Method; Female; HIV Infections; HIV-1; Humans; Male; Naltrexone; Narcotic Antagonists; Opioid-Related Disorders; Placebos; Prisoners; RNA, Viral; Viral Load | 2018 |
Efficacy of Extended-Release Naltrexone on HIV-Related and Drinking Outcomes Among HIV-Positive Patients: A Randomized-Controlled Trial.
Topics: Adult; Alcohol Drinking; Alcoholism; Anti-Retroviral Agents; CD4 Lymphocyte Count; Counseling; Delayed-Action Preparations; Double-Blind Method; Female; HIV; HIV Infections; Humans; Injections, Intramuscular; Male; Medication Adherence; Middle Aged; Naltrexone; Narcotic Antagonists; Treatment Outcome | 2019 |
Slow-release naltrexone implant versus oral naltrexone for improving treatment outcomes in people with HIV who are addicted to opioids: a double-blind, placebo-controlled, randomised trial.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anti-Retroviral Agents; CD4 Lymphocyte Count; Delayed-Action Preparations; Double-Blind Method; Female; HIV Infections; Humans; Male; Middle Aged; Naltrexone; Narcotic Antagonists; Placebos; Russia; Substance-Related Disorders; Treatment Outcome; Viral Load; Young Adult | 2019 |
Reduction in Drinking was Associated With Improved Clinical Outcomes in Women With HIV Infection and Unhealthy Alcohol Use: Results From a Randomized Clinical Trial of Oral Naltrexone Versus Placebo.
Topics: Alcohol Deterrents; Alcohol Drinking; Alcohol-Related Disorders; Anti-Retroviral Agents; CD4 Lymphocyte Count; Female; HIV Infections; Humans; Middle Aged; Naltrexone; Treatment Outcome; Viral Load | 2019 |
Design and methods of a double blind randomized placebo-controlled trial of extended-release naltrexone for alcohol dependent and hazardous drinking prisoners with HIV who are transitioning to the community.
Topics: Adult; Alcoholism; Anti-Retroviral Agents; Delayed-Action Preparations; Double-Blind Method; Health Status; HIV Infections; Humans; Medication Adherence; Mental Health; Naltrexone; Narcotic Antagonists; Prisoners; Research Design; Risk-Taking; Secondary Prevention; Socioeconomic Factors | 2014 |
An evaluation of hepatic enzyme elevations among HIV-infected released prisoners enrolled in two randomized placebo-controlled trials of extended release naltrexone.
Topics: Adult; Alanine Transaminase; Alcoholism; Aspartate Aminotransferases; Delayed-Action Preparations; Female; gamma-Glutamyltransferase; HIV Infections; Humans; Liver; Liver Function Tests; Male; Middle Aged; Naltrexone; Narcotic Antagonists; Opioid-Related Disorders; Prisoners | 2014 |
Design and methods of a double blind randomized placebo-controlled trial of extended-release naltrexone for HIV-infected, opioid dependent prisoners and jail detainees who are transitioning to the community.
Topics: Communication; Delayed-Action Preparations; Double-Blind Method; Female; HIV Infections; Humans; Injections, Intramuscular; Male; Naltrexone; Narcotic Antagonists; Opioid-Related Disorders; Patient Compliance; Prisoners; Research Design; Risk-Taking; Time Factors | 2014 |
Correlates of retention on extended-release naltrexone among persons living with HIV infection transitioning to the community from the criminal justice system.
Topics: Adult; Criminals; Delayed-Action Preparations; Double-Blind Method; Female; HIV Infections; Humans; Injections; Male; Middle Aged; Naltrexone; Narcotic Antagonists; Opiate Substitution Treatment; Opioid-Related Disorders; Patient Compliance; Transitional Care | 2015 |
Extended-release naltrexone for pre-release prisoners: A randomized trial of medical mobile treatment.
Topics: Crime; Delayed-Action Preparations; Delivery of Health Care; Female; HIV Infections; Humans; Injections, Intramuscular; Male; Medication Adherence; Mobile Health Units; Naltrexone; Narcotic Antagonists; Opioid-Related Disorders; Prisoners; Prisons; Recurrence; Risk-Taking; Substance Abuse Treatment Centers; United States | 2017 |
Feasibility and safety of extended-release naltrexone treatment of opioid and alcohol use disorder in HIV clinics: a pilot/feasibility randomized trial.
Topics: Alcoholism; British Columbia; Chicago; Delayed-Action Preparations; Feasibility Studies; Female; HIV Infections; Humans; Male; Middle Aged; Naltrexone; Narcotic Antagonists; Opioid-Related Disorders; Pilot Projects; Treatment Outcome | 2017 |
Maintenance treatment with buprenorphine and naltrexone for heroin dependence in Malaysia: a randomised, double-blind, placebo-controlled trial.
Topics: Adult; Buprenorphine; Counseling; Double-Blind Method; Heroin Dependence; HIV Infections; Humans; Malaysia; Naltrexone; Narcotic Antagonists; Recurrence; Risk-Taking; Treatment Outcome | 2008 |
Drug use and HIV risk outcomes in opioid-injecting men in the Republic of Georgia: behavioral treatment + naltrexone compared to usual care.
Topics: Adult; Behavior Therapy; Combined Modality Therapy; Counseling; Directive Counseling; Female; Georgia (Republic); HIV Infections; Humans; Male; Naltrexone; Opioid-Related Disorders; Patient Education as Topic; Risk-Taking; Substance Abuse, Intravenous; Treatment Outcome | 2012 |
Hepatic safety of injectable extended-release naltrexone in patients with chronic hepatitis C and HIV infection.
Topics: Adult; Delayed-Action Preparations; Double-Blind Method; Female; Hepatitis C, Chronic; HIV Infections; Humans; Injections, Intramuscular; Liver Function Tests; Male; Naltrexone; Narcotic Antagonists; Opioid-Related Disorders | 2012 |
Naltrexone with or without fluoxetine for preventing relapse to heroin addiction in St. Petersburg, Russia.
Topics: Adult; Antidepressive Agents, Second-Generation; Combined Modality Therapy; Double-Blind Method; Drug Therapy, Combination; Female; Fluoxetine; Heroin; Heroin Dependence; HIV Infections; Humans; Male; Naltrexone; Narcotic Antagonists; Psychotherapy; Russia; Secondary Prevention; Substance Abuse, Intravenous; Substance Withdrawal Syndrome | 2006 |
Implications of cannabis use and heavy alcohol use on HIV drug risk behaviors in Russian heroin users.
Topics: Adult; Alcohol Drinking; Cannabis; Disease Outbreaks; Female; Heroin Dependence; HIV Infections; Humans; Male; Naltrexone; Risk-Taking; Russia; Sexual Behavior; Treatment Outcome | 2008 |
23 other study(ies) available for naltrexone and HIV Infections
| Article | Year |
|---|---|
Exploration of bivalent ligands targeting putative mu opioid receptor and chemokine receptor CCR5 dimerization.
Topics: Anti-HIV Agents; Cyclohexanes; Dimerization; Dose-Response Relationship, Drug; HIV Infections; HIV-1; Humans; Ligands; Maraviroc; Microbial Sensitivity Tests; Models, Molecular; Molecular Structure; Naltrexone; Receptors, CCR5; Receptors, Opioid, mu; Structure-Activity Relationship; Triazoles | 2016 |
Perspectives on extended-release naltrexone induction among patients living with HIV and opioid use disorder: a qualitative analysis.
Topics: Delayed-Action Preparations; Female; HIV Infections; Humans; Injections, Intramuscular; Naltrexone; Narcotic Antagonists; Opioid-Related Disorders | 2021 |
The Setting-Intervention Fit of Nine Evidence-Based Interventions for Substance Use Disorders Within HIV Service Organizations Across the United States: Results of a National Stakeholder-Engaged Real-Time Delphi Study.
Topics: Buprenorphine; Delphi Technique; Evidence-Based Medicine; HIV Infections; Humans; Naltrexone; Substance-Related Disorders; United States | 2022 |
Methadone use is associated with increased levels of sCD14, immune activation, and inflammation during suppressed HIV infection.
Topics: Analgesics, Opioid; Cross-Sectional Studies; Cytokines; HIV Infections; Humans; Immunoglobulin G; Inflammation; Lipopolysaccharide Receptors; Methadone; Naltrexone; Pilot Projects; Receptors, Opioid, mu | 2022 |
Optimising opioid substitution therapy in the prison environment.
Topics: Age Factors; Buprenorphine; Comorbidity; Continuity of Patient Care; Delayed-Action Preparations; Drug Administration Schedule; England; Hepatitis C; HIV Infections; Humans; Mental Disorders; Methadone; Naltrexone; Narcotics; Needle Sharing; Opiate Substitution Treatment; Opioid-Related Disorders; Prisons; Quality Improvement; Social Work; Wales | 2019 |
Barriers and facilitators to recruitment and enrollment of HIV-infected individuals with opioid use disorder in a clinical trial.
Topics: Adult; Aged; Clinical Trials as Topic; Delayed-Action Preparations; Female; Health Services Accessibility; HIV Infections; Humans; Male; Middle Aged; Naltrexone; Opioid-Related Disorders; Patient Selection; Prospective Studies; Qualitative Research; Young Adult | 2019 |
Predictors of initiation of and retention on medications for alcohol use disorder among people living with and without HIV.
Topics: Acamprosate; Alcohol Deterrents; Alcoholism; Cohort Studies; Female; HIV Infections; Humans; Male; Middle Aged; Naltrexone; Prevalence; Veterans | 2020 |
Drug and sexual HIV-risk behaviors among adolescents and young adults with opioid use disorder.
Topics: Adolescent; Delayed-Action Preparations; Female; HIV Infections; Humans; Naltrexone; Narcotic Antagonists; Opioid-Related Disorders; Risk-Taking; Young Adult | 2021 |
Barriers to initiation of extended release naltrexone among HIV-infected adults with alcohol use disorders.
Topics: Adult; Alcohol Deterrents; Alcoholism; Cognitive Behavioral Therapy; Delayed-Action Preparations; Female; HIV Infections; Humans; Injections, Intramuscular; Male; Naltrexone; Pilot Projects; Social Stigma; Text Messaging | 2018 |
Extended-release opioid antagonists and HIV treatment.
Topics: Analgesics, Opioid; Delayed-Action Preparations; Double-Blind Method; HIV Infections; Humans; Naltrexone; Narcotic Antagonists; Treatment Outcome | 2019 |
Hepatic safety and antiretroviral effectiveness in HIV-infected patients receiving naltrexone.
Topics: Adult; Aged; Alanine Transaminase; Alcoholism; Antiretroviral Therapy, Highly Active; Aspartate Aminotransferases; CD4 Lymphocyte Count; Chemical and Drug Induced Liver Injury; Cohort Studies; Databases, Factual; Drug Interactions; Drug-Related Side Effects and Adverse Reactions; Female; HIV Infections; Humans; Liver; Liver Function Tests; Male; Middle Aged; Naltrexone; Narcotic Antagonists; Opioid-Related Disorders; RNA, Viral; Veterans | 2012 |
Methylnaltrexone antagonizes opioid-mediated enhancement of HIV infection of human blood mononuclear phagocytes.
Topics: Cells, Cultured; HIV Infections; HIV Reverse Transcriptase; Humans; Monocytes; Morphine; Naltrexone; Narcotic Antagonists; Narcotics; Quaternary Ammonium Compounds; Receptors, CCR5 | 2003 |
Morphine inhibits CD8+ T cell-mediated, noncytolytic, anti-HIV activity in latently infected immune cells.
Topics: Anti-HIV Agents; CD8-Positive T-Lymphocytes; Cell Line; HIV Infections; HIV-1; Humans; Interferon-gamma; Jurkat Cells; Morphine; Naltrexone; STAT1 Transcription Factor | 2005 |
Naltrexone inhibits alcohol-mediated enhancement of HIV infection of T lymphocytes.
Topics: Adult; Alcohol Deterrents; Alcoholism; beta-Endorphin; Cells, Cultured; Disease Susceptibility; Drug Evaluation, Preclinical; Ethanol; Female; HIV Infections; HIV Reverse Transcriptase; HIV-1; Humans; Hybrid Cells; Leukemia Virus, Murine; Lymphocytes; Male; Middle Aged; Naltrexone; Peptide Fragments; Peptides; Receptors, Opioid, mu; RNA, Messenger; Somatostatin; T-Lymphocytes; Up-Regulation; Virion; Virus Replication | 2006 |
Heroin dependence and HIV infection in Malaysia.
Topics: Adult; Buprenorphine; Demography; Female; Heroin Dependence; HIV Infections; Humans; Malaysia; Male; Naltrexone; Narcotic Antagonists; Prevalence; Risk-Taking | 2006 |
New challenges and opportunities in managing substance abuse in Malaysia.
Topics: Buprenorphine; HIV Infections; Humans; Malaysia; Mental Health Services; Naltrexone; Narcotics; Prevalence; Registries; Risk Factors; Risk-Taking; Substance-Related Disorders | 2006 |
From the Food and Drug Administration.
Topics: Alcoholism; Diabetes Mellitus, Type 2; Drug Approval; Enzyme-Linked Immunosorbent Assay; HIV Antibodies; HIV Infections; HIV-1; Humans; Metformin; Naltrexone; Saliva; United States; United States Food and Drug Administration | 1995 |
Naltrexone for lipodystrophy.
Topics: HIV Infections; Humans; Lipodystrophy; Naltrexone; Narcotic Antagonists | 2000 |
Morphine stimulates mesangial cell TNF-alpha and nitrite production.
Topics: Animals; Antibodies, Monoclonal; Cell Line, Transformed; Dose-Response Relationship, Drug; Drug Synergism; Enzyme Inhibitors; Gene Expression Regulation; Glomerular Mesangium; Glomerulosclerosis, Focal Segmental; Heroin Dependence; HIV Envelope Protein gp120; HIV Infections; Lipopolysaccharides; Macrophages; Mice; Morphine; Muscle, Smooth, Vascular; Naloxone; Naltrexone; Narcotic Antagonists; NG-Nitroarginine Methyl Ester; Nitrites; Tumor Necrosis Factor-alpha | 2000 |
Interviews and anecdotal reports.
Topics: AIDS-Related Opportunistic Infections; Anti-HIV Agents; Breast Neoplasms; CD4 Lymphocyte Count; CD8-Positive T-Lymphocytes; Complementary Therapies; Diet; Drug Therapy, Combination; HIV Infections; Humans; Hypersensitivity, Delayed; Naltrexone; Viral Load | 1998 |
Methadone enhances human immunodeficiency virus infection of human immune cells.
Topics: Adult; Drug Interactions; Fetus; HIV Infections; Humans; Immunosuppressive Agents; Macrophages; Methadone; Microglia; Middle Aged; Monocytes; Morphine; Naltrexone; Narcotics; Receptors, CCR5 | 2002 |
Effect of opioid dependence pharmacotherapies on zidovudine disposition.
Topics: Anti-HIV Agents; Buprenorphine; Drug Interactions; Female; HIV Infections; Humans; Male; Methadyl Acetate; Naltrexone; Narcotic Antagonists; Narcotics; Opioid-Related Disorders; Radioimmunoassay; Substance Abuse Detection; Time Factors; Zidovudine | 2001 |
New kinds of treatment.
Topics: Acetylmuramyl-Alanyl-Isoglutamine; Adjuvants, Immunologic; Anti-HIV Agents; Enzyme Inhibitors; HIV Infections; Humans; Naltrexone; Phorbol Esters; Topoisomerase I Inhibitors | 2001 |